0001424884-14-000037.txt : 20140401 0001424884-14-000037.hdr.sgml : 20140401 20140401144141 ACCESSION NUMBER: 0001424884-14-000037 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140401 DATE AS OF CHANGE: 20140401 EFFECTIVENESS DATE: 20140401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAPIMMUNE INC CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: NV FISCAL YEAR END: 0220 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27239 FILM NUMBER: 14733582 BUSINESS ADDRESS: STREET 1: UNIT 2 - 3590 WEST 41ST AVENUE CITY: VANCOUVER STATE: A1 ZIP: V6N 3E6 BUSINESS PHONE: 604-264-8274 MAIL ADDRESS: STREET 1: UNIT 2 - 3590 WEST 41ST AVENUE CITY: VANCOUVER STATE: A1 ZIP: V6N 3E6 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 FORMER COMPANY: FORMER CONFORMED NAME: EDUVERSE COM DATE OF NAME CHANGE: 19990827 NT 10-K 1 formnt-10k.htm formnt-10k.htm
 
 


 
 
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12B-25
NOTIFICATION OF LATE FILING

SEC File Number 000-27239

þ Form 10-K  ¨Form 20-F ¨Form 11-K ¨Form 10-Q ¨Form 10-D ¨Form N-SAR ¨Form N-CSR

For Period Ending: December 31, 2013
 
PART I: REGISTRANT INFORMATION
 
 
Full Name of Registrant: TapImmune Inc.
  
Address of Principal Executive Office:
 
1551 Eastlake Avenue East, 
Suite 100, Seattle, WA
 (206) 504-7278
 
 PART II: RULES 12B-25(B) AND (C)
 
 
It is anticipated that the subject Annual Report on Form 10-K will be filed within the next several days.
 
 
 PART III: NARRATIVE
 
 
The Registrant has not completed its Annual Report on Form 10-K for the fiscal year ended December 31, 2013 due to administrative delays.
 
 
PART IV: OTHER INFORMATION
 
 
(1) Name and telephone number of person(s) to contact in regard to this notification
 
Glynn Wilson: 206-504-7278
 
(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
 
[X] YES [ ] NO
 
 
 
 

 
 
 


(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
[ ] YES [X] NO
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
TapImmune Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
  

 
TapImmune Inc.
  
       
Dated: April 1, 2014
By:
/s/ Glynn Wilson
  
   
Glynn Wilson
  
   
CEO